133 related articles for article (PubMed ID: 7701875)
21. Low-dose methotrexate in the treatment of widespread morphea.
Seyger MM; van den Hoogen FH; de Boo T; de Jong EM
J Am Acad Dermatol; 1998 Aug; 39(2 Pt 1):220-5. PubMed ID: 9704833
[TBL] [Abstract][Full Text] [Related]
22. Cross-sectional evaluation of YKL-40 serum concentrations in patients with systemic sclerosis. Relationship with clinical and serological aspects of disease.
La Montagna G; D'Angelo S; Valentini G
J Rheumatol; 2003 Oct; 30(10):2147-51. PubMed ID: 14528508
[TBL] [Abstract][Full Text] [Related]
23. Isotretinoin in the treatment of systemic sclerosis.
Maurice PD; Bunker CB; Dowd PM
Br J Dermatol; 1989 Sep; 121(3):367-74. PubMed ID: 2803961
[TBL] [Abstract][Full Text] [Related]
24. Markers of collagen and basement membrane metabolism in sera of patients with progressive systemic sclerosis.
Guseva NG; Anikina NV; Myllylä R; Risteli L; Risteli J; Chochlova JV; Kivirikko KI; Nassonova VA
Ann Rheum Dis; 1991 Jul; 50(7):481-6. PubMed ID: 1831604
[TBL] [Abstract][Full Text] [Related]
25. Long-term therapy with plasma exchange in systemic sclerosis: effects on laboratory markers reflecting disease activity.
Cozzi F; Marson P; Rosada M; De Silvestro G; Bullo A; Punzi L; Todesco S
Transfus Apher Sci; 2001 Aug; 25(1):25-31. PubMed ID: 11791759
[TBL] [Abstract][Full Text] [Related]
26. Elevated procollagen type I carboxyterminal propeptide production in cultured scleroderma fibroblasts.
Kikuchi K; Kadono T; Fujimoto M; Ihn H; Sato S; Takehara K
Dermatology; 1995; 190(2):104-8. PubMed ID: 7727830
[TBL] [Abstract][Full Text] [Related]
27. Serum concentrations of laminin P1 and aminoterminal propeptide of type III procollagen in sickle cell disease.
Bolarin DM; Swerdlow P; Wallace AM; Littsey L
Haematologia (Budap); 1998; 29(1):51-8. PubMed ID: 9704258
[TBL] [Abstract][Full Text] [Related]
28. Serum concentration of procollagen type I carboxyterminal propeptide in localized scleroderma.
Kikuchi K; Sato S; Kadono T; Ihn H; Takehara K
Arch Dermatol; 1994 Oct; 130(10):1269-72. PubMed ID: 7944508
[TBL] [Abstract][Full Text] [Related]
29. Plasma TGF beta in systemic sclerosis: a cross-sectional study.
Snowden N; Coupes B; Herrick A; Illingworth K; Jayson MI; Brenchley PE
Ann Rheum Dis; 1994 Nov; 53(11):763-7. PubMed ID: 7826139
[TBL] [Abstract][Full Text] [Related]
30. Modification in serum concentrations of aminoterminal propeptide of type III procollagen in patients with previous transmural myocardial infarction.
Modena MG; Molinari R; Rossi R; Muia N; Castelli A; Mattioli G; Bacchella L; Gobba F
Am Heart J; 1998 Feb; 135(2 Pt 1):287-92. PubMed ID: 9489978
[TBL] [Abstract][Full Text] [Related]
31. Serum concentration of procollagen type I carboxyterminal propeptide in systemic sclerosis.
Kikuchi K; Ihn H; Sato S; Igarashi A; Soma Y; Ishibashi Y; Takehara K
Arch Dermatol Res; 1994; 286(2):77-80. PubMed ID: 8154928
[TBL] [Abstract][Full Text] [Related]
32. Aminoterminal propeptide of type III procollagen in serum during wound healing in human beings.
Haukipuro K; Risteli L; Kairaluoma MI; Risteli J
Surgery; 1990 Apr; 107(4):381-8. PubMed ID: 2321135
[TBL] [Abstract][Full Text] [Related]
33. The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction.
Høst NB; Jensen LT; Bendixen PM; Jensen SE; Koldkjaer OG; Simonsen EE
Am J Cardiol; 1995 Nov; 76(12):869-73. PubMed ID: 7484822
[TBL] [Abstract][Full Text] [Related]
34. Aminoterminal propeptide of type III procollagen in ovarian cancer. A review.
Risteli L; Risteli J; Puistola U; Tomás C; Zhu GG; Kauppila A
Acta Obstet Gynecol Scand Suppl; 1992; 155():99-103. PubMed ID: 1502898
[TBL] [Abstract][Full Text] [Related]
35. Serum aminoterminal propeptide of type III procollagen after cardiac transplantation and the effect of rejection.
Høst NB; Aldershvile J; Hørslev-Petersen K; Høyer S; Haunsø S
Am J Cardiol; 1996 Dec; 78(12):1406-10. PubMed ID: 8970415
[TBL] [Abstract][Full Text] [Related]
36. Type III collagen aminopropeptide levels in serum of patients with progressive systemic scleroderma.
Krieg T; Langer I; Gerstmeier H; Keller J; Mensing H; Goerz G; Timpl R
J Invest Dermatol; 1986 Dec; 87(6):788-91. PubMed ID: 3782862
[TBL] [Abstract][Full Text] [Related]
37. [Levels of procollagen type III n-terminal peptide (PIIINP) in serum of patients with myeloproliferative syndrome (mps)].
Podolak-Dawidziak M; Wróbel T; Jeleń M
Pol Arch Med Wewn; 1998 Jan; 99(1):24-9. PubMed ID: 9686500
[TBL] [Abstract][Full Text] [Related]
38. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment.
Meduri GU; Tolley EA; Chinn A; Stentz F; Postlethwaite A
Am J Respir Crit Care Med; 1998 Nov; 158(5 Pt 1):1432-41. PubMed ID: 9817690
[TBL] [Abstract][Full Text] [Related]
39. [The influence of heart infarction on the concentration of aminoterminal type III procollagen peptide in blood serum].
Jonderko G; Kucharz EJ; Fink M; Filipek B; Kotrys-Puchalska E; Wedrychowska A
Pol Arch Med Wewn; 1996 Dec; 96(6):520-7. PubMed ID: 9139271
[TBL] [Abstract][Full Text] [Related]
40. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial.
Black CM; Silman AJ; Herrick AI; Denton CP; Wilson H; Newman J; Pompon L; Shi-Wen X
Arthritis Rheum; 1999 Feb; 42(2):299-305. PubMed ID: 10025924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
